Latest Information

Radiofrequency Ablation, Partial Nephrectomy for RCC Offer Similar Long-Term Outcomes

January 11, 2012
In appropriately selected patients, radiofrequency ablation (RFA) is an effective minimally invasive treatment for cT1a renal cell carcinoma (RCC) that offers long-term oncologic outcomes comparable to nephron-sparing surgery, data show.

Ultrasound Not Inferior for Sizing Renal Masses

January 06, 2012
Ultrasound imaging works as well as computed tomography (CT) and magnetic resonance imaging (MRI) for evaluating renal mass size, a new study suggests.

Aveo Announces Kidney Cancer Drug Tivozanib Meets Late-Stage Goal

January 4, 2012
“The drug helped patients with advanced renal cell carcinoma live for 11.9 months without their disease progressing in a late-stage study, compared with 9.1 months for those on Nexavar [sorafenib].”

Aveo Announces Kidney Cancer Drug Tivozanib Meets Late-Stage Goal

Source: AUA Daily

The Dow Jones Newswires (1/4, Kamp, Subscription Publication) reports Aveo Pharmaceuticals Inc. announced tivozanib, a medication intended to treat advanced kidney cancer, met its goal in a late-stage trial. Dow Jones Newswires

Bloomberg News (1/4, Tirrell) reports, "The drug helped patients with advanced renal cell carcinoma live for 11.9 months without their disease progressing in a late-stage study, compared with 9.1 months for those on Nexavar [sorafenib], a medicine sold by Onyx Pharmaceuticals Inc. and Bayer AG, Aveo said." Bloomberg News

MedPage Today (1/4, Gever) adds, "Aveo and Astellas indicated that they planned to submit US and European marketing applications for tivozanib later this year." MedPage Today

Filed Under: Uncategorized